Researchers have found that combining gemcitabine with nab-paclitaxel increases intratumoral gemcitabine levels by reducing the primary metabolizing enzyme, cytidine deaminase. This combination may lead to improved patient outcomes and better administration of therapeutic treatments.
Dual inhibition of VEGF and c-MET signaling inhibits tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer. Inhibition of VEGF alone increases c-MET expression, leading to increased invasiveness and metastasis.
A study published in Cancer Prevention Research found that soy isoflavone supplements did not decrease breast cancer cell proliferation. The results are consistent with previous studies on the effectiveness of dietary supplements in preventing cancer.
Researchers have identified a new pathway that targets the root cause of glioblastoma resistance, paving the way for more effective treatments. By understanding how this complex signaling process works, scientists hope to develop novel therapies to improve patient outcomes and extend survival rates.
Researchers have identified a novel connection between two RNA-binding proteins, Musashi1 and HuR, which plays a significant role in glioblastoma development. The study suggests that disruptions to these regulatory processes can contribute to tumor formation.
Researchers found significant cancer-like gene expression changes in healthy smokers' large airway epithelia compared to nonsmokers. The study suggests smoking induces molecular alterations in the large airway epithelium prior to disease development, making it a primary site for lung cancer risk.
In a preclinical study, ganetespib slowed the growth of cancer cells from non-small cell lung tumors with a KRAS gene mutation. The drug was more active when combined with traditional lung cancer treatments and other targeted therapies, indicating its potential effectiveness in treating patients with KRAS-mutant NSCLC.
Researchers developed a sensitive test to analyze circulating tumor cells in blood, enabling clinicians to track cancer progress and treatments. The method uses high-throughput mass spectrometry analysis, allowing for the detection of genetic mutations present in small numbers of malignant cells.
Researchers identified potential gene mutations and pathway alterations that could lead to lung cancer in never-smokers. They found that these patients' tumors lacked common genes associated with lung cancer, making them ideal cases for discovering new mutations that may drive the disease.
A preclinical study found that a combination of estrogen-targeting drugs significantly reduced tobacco carcinogen-induced lung tumors in mice. The treatment, which blocks estrogen production and its effects on the body, showed maximum antitumor effects in both healthy and precancerous cells.
Researchers found sorafenib to be effective in patients with non-small cell lung cancer and a KRAS mutation, achieving a 52.6% rate of no progression at six weeks. However, median overall survival was only 5.3 months, indicating unsatisfactory outcomes.
Research finds that multicentric lung adenocarcinoma often shares the same genetic mutation, indicating a possible common origin for these tumors. The study identified genetically distinct molecular subsets using EGFR and KRAS genes.
Women with breast cancer who take anti-estrogen supplements may be decreasing their risk for melanoma. Risk for melanoma was 60 percent higher among patients who did not receive anti-estrogen therapy compared to those who received it.
Researchers discovered an agent, PEDF, that suppresses brain metastatic activity and shields the brain from tumor-induced damage. This finding represents a significant step forward in managing brain metastases, a major challenge in cancer treatment.
Researchers have identified mutations in the ATM gene as a potential risk factor for increased pancreatic cancer risk. Studies found that ATM gene mutations were present in four of 166 patients with pancreatic cancer, but absent in healthy spousal controls.
Researchers sequenced DNA from two sisters with follicular lymphoma and found identical BCL2/IGH rearrangements. The study identified 15 mutations that were present in both lymphomas, indicating a donor-recipient transmission of cancer-causing genetic material.
Women with BRCA1 or BRCA2 mutations are at high risk for developing contralateral breast cancer, and certain subgroups are more susceptible based on age and first tumor status. The study found that carriers have a 17.9% 10-year risk, while non-carriers have a 6.0% risk.
Researchers found correlations between MRI measures and histopathological markers of breast cancer, suggesting the potential for MRI in predicting disease prognosis and guiding targeted therapies. The study's findings could lead to improved understanding of breast cancer biology and more accurate treatment planning.
A large study showed that obese patients have poorer long-term outcomes than normal-weight patients when not treated with trastuzumab. Adding trastuzumab to treatment may potentially equalize disease-free survival rates among all patient groups.
Only about one-third of women undergo immediate reconstructive breast surgery after mastectomy, which improves psychological well-being and quality of life. Factors such as age, insurance status, and hospital location influence the likelihood of reconstruction, highlighting the need for increased access to this procedure.
A study published in the American Association for Cancer Research found that women who underwent bilateral oophorectomy before age 45 had lower bone mineral density and a higher prevalence of arthritis. The research suggests that clinicians should be aware of this association to provide early intervention if needed.
Researchers found that increased starch intake was associated with a greater risk of breast cancer recurrence in women. Women who increased their starch intake over one year were at a higher risk for recurring, with changes in starch intake accounting for 48% of the change in carbohydrate intake.
Researchers found that restricting carbs two days a week leads to greater weight loss and improved insulin levels compared to daily calorie restriction. This approach may be a more effective way to prevent breast cancer and other diseases, according to the study.
The addition of bevacizumab to trastuzumab and docetaxel improved progression-free survival in patients with HER2-positive, locally recurrent/metastatic breast cancer. Median progression-free survival increased by 2.8-2.9 months with bevacizumab.
Researchers confirm zoledronic acid's continued effectiveness in reducing breast cancer recurrences and improving survivorship rates among premenopausal women with estrogen receptor-positive breast cancer. The study found a 28% reduced risk for recurrence and a 36% reduction in mortality risk, with no toxic side effects.
A recent study found that clodronate had a low incidence of adverse events and toxicity among patients with breast cancer. The treatment modestly reduced the incidence of distant metastases in postmenopausal women, with a relative reduction of 9% compared to placebo.
Breast cancer mortality is higher in Hispanic women compared to non-Hispanic white women, with a 20% increased risk of death. The ethnic disparity may be attributed to tumor phenotypes less responsive to chemotherapy, which affects long-term survival rates.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer. Immediate zoledronic acid use also improved survival outcomes, particularly in women who were truly menopausal at diagnosis.
Researchers found a median progression-free interval of 7.4 months for patients treated with exemestane and everolimus, compared to 3.2 months for those receiving placebo. Clinical benefit rates were also higher in the combined treatment group, with 50.5% experiencing complete response or stable disease.
Researchers found that adding pertuzumab to trastuzumab and docetaxel chemotherapy extended progression-free survival by 6.1 months, with a 38% reduction in risk for progression. The three-drug combination was also remarkably safe and well-tolerated.
A German study found no improvement in disease-free survival among breast cancer patients treated with dose-dense chemotherapy and oral ibandronate. The results contradict previous studies, which showed benefits in postmenopausal patients receiving zoledronic acid or endocrine treatment.
Research found obesity associated with shorter time to recurrence and disease-free survival in early-stage breast cancer. However, treatment with endocrine therapy showed a protective effect against obesity-related poor outcomes.
Women treated with brachytherapy experienced a twofold increased risk for losing their breasts compared to those treated with whole-breast irradiation. Brachytherapy also led to nearly a twofold higher risk of postoperative infections and complications, as well as radiation-related side effects.
Research found that diabetes increases breast cancer risk by 37% in women diagnosed within four years of cancer development. Obesity after age 60 also significantly increases the risk, with a 55% increase in breast cancer cases compared to the general population. High and low blood lipids were also associated with different risks.
A study found significant gene expression patterns among tumor samples that correlated with distant metastatic disease development. These patterns may help personalize treatment and predict which patients are likely to recur early or late.
Researchers developed a multigene test to identify high-risk patients with ductal carcinoma in situ (DCIS) and differentiate between lower-risk and more aggressive forms. The DCIS Score algorithm predicts individual risk for recurrence, allowing physicians to provide tailored treatment programs.
Researchers discovered that the genes AURKA and MYCN were overexpressed in neuroendocrine prostate cancers, leading to the inhibition of tumor growth by PHA-739358. This study provides new hope for treating a highly lethal form of prostate cancer.
Researchers developed a new genetic screening tool to investigate possible treatments for patients with melanoma and unique genetic mutations. The study found that vemurafenib was most effective in melanomas with the V600E mutation, while vincristine only worked on those without BRAF gene mutations.
Scientists discovered that variant forms of tyrosine can slow tumor growth and prevent metastasis. This finding could lead to a simple and safe type of therapy to manage malignant disease.
Researchers have identified potential mechanisms to prevent drug-induced skin lesions in BRAF mutation-positive melanoma patients treated with current therapies. Next-generation BRAF inhibitors may also represent a novel single-agent treatment option, avoiding this side effect and extending treatment durability.
Researchers found that introducing a novel histone deacetylase inhibitor can reverse tumor's survival strategy and stop resistance, leading to higher cell death rates. This approach may prevent hormone therapy resistance in patients with estrogen receptor-positive breast cancer.
A recent study found that antifolate drugs may be effective against non-small cell lung cancer (NSCLC) patients with specific mutations in the KRAS gene. The treatment can stop the KRAS gene from being expressed, leading to cancer cell death.
Researchers developed a phenotypic screening platform to predict cancer drug success, identifying over 100 lead compounds with antitumor activity. The platform ensures unbiased analysis of complex tumor systems, revealing new interactions relevant for disease treatment.
A study suggests targeting ALK-1 with PF-03446962 may help patients whose cancer does not respond to existing antiangiogenic therapies. The agent showed partial responses and stable disease in seven out of 44 patients, including those with lung, renal or liver cancer.
A combination of REGN910 and aflibercept has been shown to inhibit tumor growth more effectively than single-agent therapies, with significant improvements in antitumor effects observed in animal models. The treatment also induced increased tumor hypoxia, leading to rapid cell death and dramatic regression in colorectal tumors.
A new study found that a novel histone deacetylase inhibitor drug, entinostat, can predict clinical benefit in breast cancer patients just days after treatment. The study showed that levels of protein lysine acetylation were related to clinical benefit, with patients who had elevated levels having a reduced risk of disease progression.
Researchers identified ALK amplification in up to 86% of inflammatory breast cancer patients, a potentially targeted therapy approach. Inhibiting ALK with a small-molecule inhibitor resulted in tumor cell death, paving the way for clinical trials.
Researchers found a significant increase in median survival time for patients with recurrent metastatic non-small cell lung cancer treated with a combination epigenetic therapy. The study, funded by SU2C and the National Cancer Institute, showed four patients achieving major objective responses to subsequent treatments.
A recombinant poxviral vaccine has shown positive responses in both metastatic breast cancer and ovarian cancer, with median overall survival ranging from 13.7 months to 15 months. The treatment led to clinical responses in some patients and mild injection-site reactions as the most common side effect.
Researchers at Dalhousie University have discovered that a specific protein, S100A10, enables macrophages to break down tissue barriers and enter the tumor site, facilitating cancer cell growth and metastasis. This finding presents a potential target for blocking tumor growth by inhibiting S100A10 activity.